» Articles » PMID: 26826462

Genetic Analysis and Functional Characterization of Novel Mutations in a Series of Patients with Atypical Hemolytic Uremic Syndrome

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disorder caused by dysregulation of the complement alternative pathway, and associated with mutations in genes of complement components and regulators. In the recent years several studies have been published describing these mutations, however, no data is available from the Central and Eastern European region. In this study we present a detailed genetic analysis of our 30 patients, hospitalized with the diagnosis of aHUS in the past 7 years. We analyzed the genetic variants of genes CFH, CFI, CD46, THBD, CFB and C3; furthermore the possible effect of mutations that may alter the function or level of factor H protein was also investigated. We identified 27 (12 novel and 15 previously described) potentially disease-causing mutations in the candidate genes in 23 patients. Genetic analysis of family members revealed that in most cases the disease develops in individuals with multiple genetic risk factors, which may explain the low penetrance of the mutations. Here we showed that two novel mutations (p.W198R, p.P1161T) and a previously reported one (p.R1215Q) in CFH caused impaired regulation as indicated by increased lysis in hemolytic test, while four CFH mutations (p.V609D, p.S722X, p.T1216del and p.C448Y) were associated with decreased factor H protein level in serum as determined by allele-specific immunoassay. These results further point to the necessity of complete genetic workup of patients with aHUS and to the importance of functional characterization of novel variations.

Citing Articles

Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort.

Hallam T, Andreadi A, Sharp S, Brocklebank V, Gardenal E, Dreismann A J Biol Chem. 2024; 300(7):107452.

PMID: 38852887 PMC: 11277764. DOI: 10.1016/j.jbc.2024.107452.


Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP.

Kelen K, Horvath O, Kis E, Mikes B, Sallay P, Prohaszka Z Int J Mol Sci. 2023; 24(18).

PMID: 37762692 PMC: 10531618. DOI: 10.3390/ijms241814389.


Genetic investigation of Nordic patients with complement-mediated kidney diseases.

Rydberg V, Aradottir S, Kristoffersson A, Svitacheva N, Karpman D Front Immunol. 2023; 14:1254759.

PMID: 37744338 PMC: 10513385. DOI: 10.3389/fimmu.2023.1254759.


Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report.

Rysava R, Peiskerova M, Tesar V, Benes J, Kment M, Szilagyi A Front Immunol. 2022; 13:1001366.

PMID: 36275662 PMC: 9580272. DOI: 10.3389/fimmu.2022.1001366.


Complement Factor I Variants in Complement-Mediated Renal Diseases.

Zhang Y, Goodfellow R, Ghiringhelli Borsa N, Dunlop H, Presti S, Meyer N Front Immunol. 2022; 13:866330.

PMID: 35619721 PMC: 9127439. DOI: 10.3389/fimmu.2022.866330.